fluoxetine has been researched along with Disease, Pulmonary in 8 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of the present study was to investigate the involvement of OPN in fluoxetine amelioration of monocrotaline (MCT)-induced pulmonary inflammation and vascular remodelling in rats." | 7.77 | Downregulation of osteopontin is associated with fluoxetine amelioration of monocrotaline-induced pulmonary inflammation and vascular remodelling. ( Han, DD; Liu, M; Wang, HL; Wang, HM; Wang, Y; Zhang, XH, 2011) |
| " The aim of the present study was to investigate the involvement of OPN in fluoxetine amelioration of monocrotaline (MCT)-induced pulmonary inflammation and vascular remodelling in rats." | 3.77 | Downregulation of osteopontin is associated with fluoxetine amelioration of monocrotaline-induced pulmonary inflammation and vascular remodelling. ( Han, DD; Liu, M; Wang, HL; Wang, HM; Wang, Y; Zhang, XH, 2011) |
| " Additional studies are needed to determine the effects of chronic administration of amphetamines on circulating 5-HT." | 1.33 | Amphetamine analogs increase plasma serotonin: implications for cardiac and pulmonary disease. ( Baumann, MH; Rothman, RB; Zolkowska, D, 2006) |
| "Each was an elderly white female with pulmonary disease and atrial arrhythmias, including atrial fibrillation, and each was prescribed diuretics, nitrates, and other cardiac and/or pulmonary agents." | 1.28 | Unexpected deaths in depressed medical inpatients treated with fluoxetine. ( Frontera, MA; Spier, SA, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (50.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kowal-Bielecka, O | 1 |
| Fransen, J | 1 |
| Avouac, J | 1 |
| Becker, M | 1 |
| Kulak, A | 1 |
| Allanore, Y | 1 |
| Distler, O | 1 |
| Clements, P | 1 |
| Cutolo, M | 1 |
| Czirjak, L | 1 |
| Damjanov, N | 1 |
| Del Galdo, F | 1 |
| Denton, CP | 1 |
| Distler, JHW | 1 |
| Foeldvari, I | 1 |
| Figelstone, K | 1 |
| Frerix, M | 1 |
| Furst, DE | 1 |
| Guiducci, S | 1 |
| Hunzelmann, N | 1 |
| Khanna, D | 1 |
| Matucci-Cerinic, M | 1 |
| Herrick, AL | 1 |
| van den Hoogen, F | 1 |
| van Laar, JM | 1 |
| Riemekasten, G | 1 |
| Silver, R | 1 |
| Smith, V | 1 |
| Sulli, A | 1 |
| Tarner, I | 1 |
| Tyndall, A | 1 |
| Welling, J | 1 |
| Wigley, F | 1 |
| Valentini, G | 1 |
| Walker, UA | 1 |
| Zulian, F | 1 |
| Müller-Ladner, U | 1 |
| Wang, Y | 1 |
| Han, DD | 1 |
| Wang, HM | 1 |
| Liu, M | 1 |
| Zhang, XH | 1 |
| Wang, HL | 1 |
| Zolkowska, D | 1 |
| Rothman, RB | 1 |
| Baumann, MH | 1 |
| de Kerviler, E | 1 |
| Trédaniel, J | 1 |
| Revlon, G | 1 |
| Groussard, O | 1 |
| Zalcman, G | 1 |
| Ortoli, JM | 1 |
| Espié, M | 1 |
| Hirsch, A | 1 |
| Frija, J | 1 |
| Haro Estarriol, M | 1 |
| Rubio Goday, M | 1 |
| Puig, J | 1 |
| Bass, SP | 1 |
| Colebatch, HJ | 1 |
| Davies, LP | 1 |
| Spier, SA | 1 |
| Frontera, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Aiming to Reduce Disease-related Gastrointestinal Symptoms in Systemic Sclerosis by Repeat Intestinal Infusions of Anaerobic Cultivated Human Intestinal Microbiome (ACHIM); a Randomized, Double-blind Placebo-controlled 20 Week Study[NCT04300426] | Phase 2 | 75 participants (Actual) | Interventional | 2020-09-24 | Completed | ||
| "Effect of a Pulmonary Rehabilitation Program in Patients With Interstitial Lung Disease Associated With Systemic Sclerosis on Oxygen Consumption, Functionality, and Quality of Life"[NCT06105073] | 67 participants (Anticipated) | Observational [Patient Registry] | 2022-03-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for fluoxetine and Disease, Pulmonary
| Article | Year |
|---|---|
Update of EULAR recommendations for the treatment of systemic sclerosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Delphi Technique; Endothelin Receptor Antagonists; Europe; | 2017 |
Update of EULAR recommendations for the treatment of systemic sclerosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Delphi Technique; Endothelin Receptor Antagonists; Europe; | 2017 |
Update of EULAR recommendations for the treatment of systemic sclerosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Delphi Technique; Endothelin Receptor Antagonists; Europe; | 2017 |
Update of EULAR recommendations for the treatment of systemic sclerosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Delphi Technique; Endothelin Receptor Antagonists; Europe; | 2017 |
7 other studies available for fluoxetine and Disease, Pulmonary
| Article | Year |
|---|---|
Downregulation of osteopontin is associated with fluoxetine amelioration of monocrotaline-induced pulmonary inflammation and vascular remodelling.
Topics: Animals; Dose-Response Relationship, Drug; Down-Regulation; Fluoxetine; Inflammation; Lung; Lung Dis | 2011 |
Amphetamine analogs increase plasma serotonin: implications for cardiac and pulmonary disease.
Topics: Amphetamines; Animals; Central Nervous System Stimulants; Dextroamphetamine; Dose-Response Relations | 2006 |
Fluoxetin-induced pulmonary granulomatosis.
Topics: Antidepressive Agents, Second-Generation; Depressive Disorder; Diagnosis, Differential; Female; Fluo | 1996 |
[Pulmonary disease associated with fluoxetine administration].
Topics: Aged; Antidepressive Agents, Second-Generation; Biopsy; Female; Fluoxetine; Follow-Up Studies; Human | 2002 |
Fluoxetine-induced lung damage.
Topics: Female; Fluoxetine; Humans; Lung Diseases; Middle Aged | 1992 |
Fluoxetine-induced lung damage.
Topics: Animals; Female; Fluoxetine; Humans; Lung Diseases; Middle Aged; Rats; Zimeldine | 1992 |
Unexpected deaths in depressed medical inpatients treated with fluoxetine.
Topics: Aged; Arrhythmias, Cardiac; Death, Sudden; Depressive Disorder; Female; Fluoxetine; Humans; Inpatien | 1991 |